News - HANGZHOU DAC BIOTECHNOLOGY CO.,LTD

杭州多禧生物科技有限公司

EN

Search

杭州多禧生物科技有限公司

EN

中文
EN

News

Company News

News

Company News

News

ASCO 2026: DXC006 Shows Robust Efficacy and a Favorable Safety Profile in Small Cell Lung Cancer in Phase I Clinical Trial

Hangzhou, June1, 2026 — DXC006, a first-in-class anti-CD56 ADC developed by Hangzhou DAC Biotechnology Co., Ltd. ...
More

02

2026.06
Hangzhou DAC Biotech Enters a New Strategic Agreement on Novel Antibody-Drug Conjugates (ADCs) with Whitehawk Therapeutics

Hangzhou, China, May 22, 2026:Following the closing of trading on the New York Stock Market, Whitehawk Therapeutic...
More

22

2026.05
A senior Oncology management team from J&J Innovation Medicine visited Hangzhou DAC

On September 10,2025,a senior Oncology management team from Johnson & Johnson Innovation Medicine visited Hangzhou DAC Biotechnology Co., Ltd.
More

12

2025.09
Hangzhou DAC, WuXi Biologics and Aadi Bioscience Entered into Collaboration Agreements for Three Noval Antibody-Drug Conjugates (ADCs)

Hangzhou DAC, WuXi Biologics and Aadi Bioscience Entered into Collaboration Agreements for Three Noval Antibody-...
More

20

2024.12
Hangzhou DAC Biotechnology Announces a Collaboration and License Agreement with Janssen for the Development of Novel Antibody-Drug Conjugates

Hangzhou, China, June 1st, 2022 -- Hangzhou DAC Biotechnology Co., Ltd. (“DAC Biotechnology”) today announced a ...
More

01

2022.06

HANGZHOU DAC BIOTECHNOLOGY CO.,LTD

Address

369 Qiaoxin Road, Xiasha Subdistrict, Qiantang District, Hangzhou, Zhejiang, China
Telephone

0571-56050590
Email

duoxi@dacbiotech.com

Official accounts

Official accounts

Official accounts

Links

Links

Center For DRUG EVALUTION NMPA

Copyright©2016杭州多禧生物科技有限公司 All Rights Reserved 版权所有备案号：浙ICP备13027807号